ArticleFrontiers in surgery2026
Intravesical hyaluronic acid and chondroitin sulphate for recurrent urinary tract infections: a prospective multicentre comparison of two instillation protocols.
Article in Frontiers in surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Recurrent urinary tract infections (r-UTIs) are highly prevalent in women and are associated with reduced quality of life and increased healthcare burden. Intravesical glycosaminoglycan (GAG) replenishment with hyaluronic acid (HA) and chondroitin sulphate (CS) has shown clinical benefit, but the optimal instillation schedule remains undefined. This study aimed to compare the safety and effectiveness of two HA + CS instillation protocols in women with r-UTIs. Methods: In this prospective multicentre observational study, women ≥18 years with r-UTIs, defined according to European Association of Urology guidelines, were enrolled. Patients received HA + CS according to institutional practice: Group A (weekly instillations for 4 weeks followed by monthly maintenance for 12 months) or Group B (weekly instillations for 8 weeks followed by monthly maintenance for 12 months). Clinical evaluation, 3-day bladder diary, uroflowmetry (UF), post-void residual (PVR), visual analogue scale (VAS) for pelvic pain, urinalysis, urine culture, and ICIQ-FLUTS questionnaire were assessed at baseline and during follow-up (1, 3, 6, and 12 months). The primary outcome was the cumulative number of UTI episodes recorded throughout the entire 12-month follow-up period. Results: A total of 140 women (70 per group) were included. At 12 months, mean UTI episodes decreased to 0.6 ± 0.5 in Group A and 0.7 ± 0.3 in Group B, without significant between-group differences ( Conclusion: Intravesical HA + CS significantly reduced UTI recurrence and improved urinary symptoms over 12 months. No statistically significant differences in clinical outcomes were observed between the two treatment groups over the 12-month follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.